Exane Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Exane Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,011	Closed	-$669K	–	17
2020 Q1	$669K	Sell	12,011 -19,578	-62%	-$1.2M	1.31%	11
2019 Q4	$2.03M	Sell	31,589 -171,268	-84%	-$9.81M	2.49%	11
2019 Q3	$10.3M	Sell	202,857 -32,613	-14%	-$1.53M	7.9%	2
2019 Q2	$10.7M	Sell	235,470 -78,425	-25%	-$3.65M	4.74%	6
2019 Q1	$15M	Buy	313,895 +255,502	+438%	+$12.7M	7.29%	3
2018 Q4	$3.04M	Sell	58,393 -266,748	-82%	-$14.3M	1.78%	13
2018 Q3	$20.2M	Sell	325,141 -50,696	-13%	-$3.01M	6.32%	1
2018 Q2	$20.8M	Sell	375,837 -145,669	-28%	-$7.87M	9%	2
2018 Q1	$33M	Buy	521,506 +138,180	+36%	+$8.89M	9.9%	1
2017 Q4	$23.5M	Sell	383,326 -90,435	-19%	-$5.66M	7.3%	4
2017 Q3	$30.2M	Sell	473,761 -80,601	-15%	-$4.71M	5.9%	4
2017 Q2	$30.9M	Buy	554,362 +34,226	+7%	+$1.86M	9.63%	1
2017 Q1	$28.3M	Buy	520,136 +244,907	+89%	+$13.4M	8.77%	2
2016 Q4	$16.1M	Buy	275,229 +134,704	+96%	+$7.36M	5.3%	8
2016 Q3	$7.58M	Buy	+140,525	New	+$9.03M	2.38%	21

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Exane Asset Management's BMY Position: Q2 2020 in Review

Exane Asset Management sold out of Bristol-Myers Squibb (BMY) in Q2 2020, closing a stake of 12,011 shares — an estimated $669K sold.

Exane Asset Management first reported a position in BMY in Q3 2016 and held it in 15 quarters. The position peaked at $33M in Q1 2018. 2,189 funds tracked by Wall St. Rank hold BMY as of Q2 2020.

Exane Asset Management reported no remaining Bristol-Myers Squibb position as of Q2 2020 after selling out during the quarter.
Exane Asset Management sold 12,011 Bristol-Myers Squibb shares in Q2 2020, an estimated $669K.
Exane Asset Management first reported a position in Bristol-Myers Squibb in Q3 2016 and held it in 15 quarters.
Exane Asset Management's Bristol-Myers Squibb position peaked at $33M in Q1 2018.
2,189 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2020.

Based on Exane Asset Management's 13F filing for Q2 2020, filed 27 Jul 2020.